Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 131 SGMIB-anti-HER2 VHH1

A monoclonal antibody (MoAb) directed against the human epidermal growth factor receptor 2 (HER2; ERBB2) labeled with iodine I 131 using the residualizing radio-iodinating reagent N-succinimidyl 4-guanidinomethyl 3-iodobenzoate (SGMIB), with potential radiotherapeutic and radioimaging activities upon positron emission tomography (PET). Upon administration of iodine I 131 SGMIB-anti-HER2 VHH1, the HER2 MoAb moiety selectively targets and binds to HER2-expressing tumor cells. Upon PET imaging, tumor cells can be visualized. In addition, the iodine I 131 moiety of VHH1 selectively delivers a cytotoxic dose of iodine I 131 to the tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. SGMIB improves tumor retention of radioactivity and decreases exocytosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[131I]-SGMIB anti-HER2 VHH1
iodine I 131 N-succinimidyl 4-guanidinomethyl-3-iodobenzoate-anti-HER2 VHH1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search